CIBC Asset Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q3
Sell
-66,367
Closed -$642K 1505
2021
Q2
$642K Buy
66,367
+9,040
+16% +$85.1K ﹤0.01% 762
2021
Q1
$614K Sell
57,327
-59,773
-51% -$739K ﹤0.01% 751
2020
Q4
$1.72M Buy
117,100
+67,694
+137% +$976K 0.01% 513
2020
Q3
$701K Buy
+49,406
New +$493K ﹤0.01% 643

Other funds holding TRIL

CIBC Asset Management's TRIL Position: Q3 2021 in Review

CIBC Asset Management sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 66,367 shares — an estimated $642K sold.

CIBC Asset Management first reported a position in TRIL in Q3 2020 and held it in 4 quarters. The position peaked at $1.72M in Q4 2020. 181 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • CIBC Asset Management reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • CIBC Asset Management sold 66,367 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $642K.
  • CIBC Asset Management first reported a position in Trillium Therapeutics Inc. in Q3 2020 and held it in 4 quarters.
  • CIBC Asset Management's Trillium Therapeutics Inc. position peaked at $1.72M in Q4 2020.
  • 181 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on CIBC Asset Management's 13F filing for Q3 2021, filed 9 Nov 2021.